ALNYLAM PHARMACEUTICALS, INC. Uncategorized Contracts & Agreements
53 Contracts & Agreements
- Amendment No (Filed With SEC on May 2, 2024)
- Letter Agreement, effective as of March 1, 2024, between the Company and Indrani L. Franchini (Filed With SEC on March 4, 2024)
- Letter Agreement, dated July 31, 2023, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D (Filed With SEC on August 3, 2023)
- Amendment No. 1 entered into as (Filed With SEC on August 3, 2023)
- Cross-License Agreement dated as of November 12, 2012 by and among the Registrant, Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) and Protiva... (Filed With SEC on February 23, 2023)
- Form of Capped Call Transaction Confirmation (Filed With SEC on September 16, 2022)
- Letter Agreement between the Registrant and (Filed With SEC on April 28, 2022)
- Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D (Filed With SEC on October 28, 2021)
- Letter Agreement between the Registrant and Laurie B. Keating dated September 6, 2021 (Filed With SEC on October 28, 2021)
- Supplemental Agreement effective July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
- Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009 (Filed With SEC on August 3, 2021)
- Sponsored Research Agreement dated as of July 27, 2009 by and among the (Filed With SEC on August 3, 2021)
- Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020 (Filed With SEC on November 5, 2020)
- First Amendment to (Filed With SEC on November 5, 2020)
- Co-Development Agreement between the Registrant and BXLS (Filed With SEC on November 5, 2020)
- Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant (Filed With SEC on August 6, 2020)
- Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation (Filed With SEC on August 6, 2019)
- Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc (Filed With SEC on August 6, 2019)
- 300 Third Street Cambridge MA, 02142 main ###-###-#### fax ###-###-#### (Filed With SEC on August 9, 2017)
- 300 Third StreetCambridge MA, 02142main 617.551.8200fax ###-###-#### (Filed With SEC on February 15, 2017)
- 300 ThirdStreet Cambridge MA, 02142 main ###-###-#### fax ###-###-#### (Filed With SEC on February 12, 2016)
- LETTER AGREEMENT (Filed With SEC on November 6, 2014)
- INVESTOR AGREEMENT BYAND BETWEEN GENZYME CORPORATION AND ALNYLAMPHARMACEUTICALS, INC. DATED AS OF FEBRUARY 27, 2014 (Filed With SEC on May 9, 2014)
- FIRST AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on February 27, 2014)
- 65 Hayden Avenue, Lexington, MA 02421 P ###-###-#### F ###-###-#### www.cubist.com (Filed With SEC on February 19, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions (Filed With SEC on February 19, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 19, 2013)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on February 19, 2013)
- [Signature Page follows] (Filed With SEC on November 5, 2012)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 5, 2012)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on November 3, 2011)
- Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 29, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on May 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on May 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on May 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on May 5, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on February 18, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on February 18, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on February 18, 2011)
- EX-101 INSTANCE DOCUMENT (Filed With SEC on February 18, 2011)
